{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:52:50Z","timestamp":1777099970028,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014452","name":"University of Cincinnati College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ccm.2025.07.012","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:42:47Z","timestamp":1758577367000},"page":"739-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary Manifestations of Lysosomal Storage Disorders in Adults"],"prefix":"10.1016","volume":"46","author":[{"given":"Siddhartha","family":"Narayanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Catherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Pajor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis X.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"160","key":"10.1016\/j.ccm.2025.07.012_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0363-2020","article-title":"Interstitial lung disease in lysosomal storage disorders","volume":"30","author":"Borie","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.ccm.2025.07.012_bib2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/crj.13150","article-title":"Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: a state-of-the art review","volume":"14","author":"Jezela-Stanek","year":"2020","journal-title":"Clin Res J"},{"issue":"2","key":"10.1016\/j.ccm.2025.07.012_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/ijms20020327","article-title":"Molecular pathways and respiratory involvement in lysosomal storage diseases","volume":"20","author":"Faverio","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"10.1016\/j.ccm.2025.07.012_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","article-title":"Types A and B Niemann-Pick disease","volume":"120","author":"Schuchman","year":"2017","journal-title":"Mol Genet Metabol"},{"issue":"1","key":"10.1016\/j.ccm.2025.07.012_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99921-6","article-title":"Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective","volume":"11","author":"Pokrzywinski","year":"2021","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.ccm.2025.07.012_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312870","article-title":"Acid sphingomyelinase deficiency: a clinical and immunological perspective","volume":"22","author":"Pinto","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ccm.2025.07.012_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13023-019-1029-1","article-title":"Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up","volume":"14","author":"Lipi\u0144ski","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ccm.2025.07.012_bib8","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.923394","article-title":"Combined emphysema and interstitial lung disease as a rare presentation of pulmonary involvement in a patient with chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B)","volume":"21","author":"Opoka","year":"2020","journal-title":"Am J Case Rep"},{"issue":"2","key":"10.1016\/j.ccm.2025.07.012_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/biom14020211","article-title":"The genetic basis, lung involvement, and therapeutic options in Niemann-Pick disease: a comprehensive review","volume":"14","author":"Tirelli","year":"2024","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.ccm.2025.07.012_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/gim.2017.7","article-title":"Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency","volume":"19","author":"McGovern","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.ccm.2025.07.012_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","article-title":"Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)","volume":"12","author":"McGovern","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.ccm.2025.07.012_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107563","article-title":"Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to gaucher disease","volume":"139","author":"Oliva","year":"2023","journal-title":"Mol Genet Metabol"},{"issue":"5","key":"10.1016\/j.ccm.2025.07.012_bib13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","article-title":"Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months","volume":"41","author":"Wasserstein","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.ccm.2025.07.012_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","article-title":"Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)","volume":"126","author":"Wasserstein","year":"2019","journal-title":"Mol Genet Metabol"},{"issue":"5","key":"10.1016\/j.ccm.2025.07.012_bib15","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s12325-023-02453-w","article-title":"Healthcare service use patterns among patients with acid sphingomyelinase deficiency type B: a retrospective US claims analysis","volume":"40","author":"Pulikottil-Jacob","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.ccm.2025.07.012_bib16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.21873\/invivo.13457","article-title":"The long-term lung and respiratory outcomes of acid sphingomyelinase deficiency: a 10- and 20-year Follow-up study","volume":"38","author":"Huang","year":"2024","journal-title":"In Vivo (Athens)"},{"key":"10.1016\/j.ccm.2025.07.012_bib17","article-title":"Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: a retrospective chart review study","volume":"38","author":"Pulikottil-Jacob","year":"2023","journal-title":"Mol Genet Metab Rep"},{"issue":"5","key":"10.1016\/j.ccm.2025.07.012_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.revmed.2016.10.387","article-title":"Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: a retrospective multicentric study of 28 adult cases","volume":"38","author":"Lidove","year":"2017","journal-title":"Rev Med Interne"},{"issue":"1","key":"10.1016\/j.ccm.2025.07.012_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","article-title":"Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A\/B)","volume":"18","author":"Geberhiwot","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.ccm.2025.07.012_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","article-title":"Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): literature review and report of new cases","volume":"118","author":"Cassiman","year":"2016","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.ccm.2025.07.012_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gte.1997.1.5","article-title":"Gaucher disease: gene frequencies and genotype\/phenotype correlations","volume":"1","author":"Grabowski","year":"1997","journal-title":"Genet Test"},{"key":"10.1016\/j.ccm.2025.07.012_bib22","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ccm.2025.07.012_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3","volume":"143","author":"Goker-Alpan","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.ccm.2025.07.012_bib24","series-title":"Metabolic and molecular bases of inherited disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"2001"},{"key":"10.1016\/j.ccm.2025.07.012_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol Genet Metabol"},{"issue":"2","key":"10.1016\/j.ccm.2025.07.012_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ccm.2025.07.012_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","article-title":"'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature","volume":"31","author":"Biegstraaten","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ccm.2025.07.012_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ymgme.2021.06.009","article-title":"Throwing a spotlight on under-recognized manifestations of Gaucher disease: pulmonary involvement, lymphadenopathy and Gaucheroma","volume":"133","author":"Ramaswami","year":"2021","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.ccm.2025.07.012_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1056\/NEJM199701303360516","article-title":"Gaucher cells in pulmonary-capillary blood in association with pulmonary hypertension","volume":"336","author":"Ross","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2025.07.012_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.ccm.2025.07.012_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ccm.2025.07.012_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/(SICI)1096-8628(20000320)91:3<222::AID-AJMG13>3.0.CO;2-#","article-title":"Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: molecular and pathological analyses","volume":"91","author":"Finn","year":"2000","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.ccm.2025.07.012_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0004.1978.tb04242.x","article-title":"Synthetic substrate beta-glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease","volume":"13","author":"Wenger","year":"1978","journal-title":"Clin Genet"},{"issue":"Suppl 3","key":"10.1016\/j.ccm.2025.07.012_bib34","article-title":"Misdiagnosis of Niemann-Pick disease type C as Gaucher disease","volume":"33","author":"Lo","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ccm.2025.07.012_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ccm.2025.07.012_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","article-title":"Revised recommendations for the management of Gaucher disease in children","volume":"172","author":"Kaplan","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ccm.2025.07.012_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","article-title":"Gaucher disease: pathological mechanisms and modern management","volume":"129","author":"Jmoudiak","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ccm.2025.07.012_bib38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-3476(95)70358-6","article-title":"Outcome of partial splenectomy for type I Gaucher disease","volume":"126","author":"Zimran","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.ccm.2025.07.012_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9610(91)90363-I","article-title":"A 27-year experience with splenectomy for Gaucher's disease","volume":"161","author":"Fleshner","year":"1991","journal-title":"Am J Surg"},{"issue":"8","key":"10.1016\/j.ccm.2025.07.012_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/qjmed\/94.8.407","article-title":"Lung involvement and enzyme replacement therapy in Gaucher's disease","volume":"94","author":"Goitein","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.ccm.2025.07.012_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.21305","article-title":"Life expectancy in Gaucher disease type 1","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ccm.2025.07.012_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.annder.2016.10.010","article-title":"Maladie de Fabry [Fabry disease]","volume":"144","author":"Stephan","year":"2017","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ccm.2025.07.012_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltim)"},{"issue":"33","key":"10.1016\/j.ccm.2025.07.012_bib44","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","article-title":"Anderson-Fabry disease: a multiorgan disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ccm.2025.07.012_bib45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2025.07.012_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020271","article-title":"Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions","volume":"11","author":"Kok","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ccm.2025.07.012_bib47","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.85.11.3903","article-title":"Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region","volume":"85","author":"Bishop","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.ccm.2025.07.012_bib48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejim.2013.05.003","article-title":"Pulmonary involvement in Fabry disease: overview and perspectives","volume":"24","author":"Franzen","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ccm.2025.07.012_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","article-title":"Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease","volume":"289","author":"Brady","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2025.07.012_bib50","first-page":"105","article-title":"Spirometric abnormalities in patients with Fabry disease and effect of enzyme replacement therapy","volume":"447","author":"Barbey","year":"2005","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ccm.2025.07.012_bib51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.ccm.2025.07.012_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ccm.2025.07.012_bib53","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ccm.2025.07.012_bib54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2025.07.012_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.02490607","article-title":"Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test","volume":"3","author":"Andrade","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ccm.2025.07.012_bib56","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","article-title":"Fabry disease 'the new great imposter': results of the French observatoire in internal medicine departments (FIMeD)","volume":"81","author":"Lidove","year":"2012","journal-title":"Clin Genet"},{"key":"10.1016\/j.ccm.2025.07.012_bib57","first-page":"1004","article-title":"[Fabry disease--a diagnostic and therapeutic challenge]","volume":"125","author":"Houge","year":"2005","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.1016\/j.ccm.2025.07.012_bib58","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2025.07.012_bib59","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ccm.2025.07.012_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ccm.2025.07.012_bib61","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.ccm.2025.07.012_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027252312500067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027252312500067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:56:09Z","timestamp":1760810169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027252312500067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S027252312500067X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2025.07.012","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Manifestations of Lysosomal Storage Disorders in Adults","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2025.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}